Memphasys secures New Zealand deal for 1,200 cartridges
Key points
- Memphasys secured a two-year commercial agreement with Health New Zealand to supply its Felix sperm preparation technology to Fertility Plus.
- The agreement mandates a minimum delivery of 1,200 Felix cartridges and one console, while the company's shares remained unchanged at $0.004.
- Memphasys stated that the supply deal supports its strategy to expand direct clinic sales and generate recurring consumables revenue.
Memphasys (ASX:MEM) secured a two-year public healthcare agreement in New Zealand covering a minimum of 1,200 Felix cartridges.
The contract marks the company's first commercial agreement in New Zealand, following earlier distribution deals across Europe, Asia, and the Middle East.
Under the terms, an initial shipment will deliver 500 cartridges and one Felix console to Auckland's Fertility Plus clinic.
Marjan Mikel, Chair of the Memphasys Commercialization Committee, commented, “The commitment to purchase 1,200 cartridges provides a strong foundation in New Zealand, where we intend to operate directly alongside Australia to protect margins and deliver excellent customer support.”
Memphasys stated that the agreement will support its strategy to secure long-term clinic relationships and generate recurring consumables revenue.
Following the announcement, the Memphasys share price was unchanged at $0.004.
The company stated that it is focused on establishing a direct-to-clinic sales presence across Australia and New Zealand to protect operating margins.
Memphasys added that it continues to focus on growing its global clinic base and converting adoption into repeat cartridge sales.
